NeurAxis: Insights on Upcoming Third Quarter Results Call
CARMEL, Ind. – NeurAxis, Inc. (NYSE American: NRXS), a pioneering medical technology firm, is gearing up to share its financial results for the third quarter of 2025. This release will cover the period ending September 30, 2025, and is set to occur before the market opens on Tuesday, November 11, 2025.
Conference Call Scheduled
The details of the eagerly anticipated conference call have been established. NeurAxis will host this session on the same day, starting at 9:00 am ET. This call will offer insights into their financial performance and strategic direction, providing valuable information to investors and stakeholders alike.
How to Participate
Interested participants will have the option to join the conference call through a live webcast. This webcast will be accessible through the Investor Relations section of NeurAxis's official website. Participants will be able to engage in the session by submitting questions via the “Ask a Question” link during the webcast or by sending inquiries through the provided email: NRXS@lythampartners.com.
Dial-in Information
For those who prefer to join the call via phone, registration is required before participation. After completing the registration process, participants will receive their dial-in details and a unique PIN, along with a confirmation email. This ensures that everyone has the necessary information to connect smoothly.
Webcast Replay Availability
Attendees who cannot join live will have a chance to review the discussions, as a replay of the webcast will be provided afterward. The recorded session will also be available in the Investor Relations section of NeurAxis’s website, ensuring that all interested parties can stay updated on the company's developments.
About NeurAxis, Inc.
NeurAxis is at the forefront of medical technology, specializing in neuromodulation therapies aimed at treating chronic conditions that significantly affect patients. Their flagship therapy, IB-Stim™, represents cutting-edge technology in the form of Percutaneous Electrical Nerve Field Stimulation (PENFS). Notably, this innovative therapy has received FDA clearance for treating functional abdominal pain linked to irritable bowel syndrome (IBS) in adolescents aged 8 to 21 years.
Innovations in Clinical Trials
NeurAxis is committed to pushing the boundaries of medical science through rigorous clinical trials. The company is currently pursuing additional studies using PENFS technology in both pediatric and adult populations with various unmet medical needs. By leveraging evidence-based practices, NeurAxis aims to enhance the adoption of their therapies within healthcare communities.
Contact Information
For more inquiries, NeurAxis encourages communication through the following channels:
Company Contact:
NeurAxis, Inc.
Email: info@neuraxis.com
For Investor Relations:
Ben Shamsian
Lytham Partners
Phone: 646-829-9701
Email: shamsian@lythampartners.com
Frequently Asked Questions
What is the purpose of the NeurAxis conference call?
The call aims to discuss the financial results for Q3 2025, providing insights for investors and stakeholders regarding the company’s performance.
How can I access the NeurAxis conference call?
Participants can access the call via a live webcast on the Investor Relations section of the company's website after registration.
What technology does NeurAxis specialize in?
NeurAxis specializes in neuromodulation therapies, particularly its proprietary IB-Stim™ therapy for treating conditions like IBS.
When will the Q3 2025 results be reported?
The results will be reported on Tuesday, November 11, 2025, before market opening.
Who can I contact for more information?
You can reach out to NeurAxis directly through the provided company email or by contacting the investor relations representative, Ben Shamsian.